Wnt Signaling Pathway Inhibitors Pipeline: Do You Really Need It? This Will Help You Decide!

Wnt signaling pathway plays an important role in embryonic development. The signaling pathway regulates cell-to-cell interaction, accelerates trophoblast development, activates blastocyst, accelerate chorion-allantois fusion and implantation. A wide range of diseases, such as different types of cancer and degenerative diseases can be treated by deregulation of components involved in Wnt/β-catenin signaling pathway. Also, researchers have demonstrated that moderate weakening of Wnt signaling can eliminate its carcinogenic potential. Based on the recent researches, Wnt Signaling Pathway inhibitors have also shown potential in cardiovascular disorders.

Download the sample report @ https://www.pharmaproff.com/request-sample/1210

According to a new research report “Wnt Signaling Pathway Inhibitors – Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, Wnt Signaling Pathway Inhibitors therapeutics currently exhibits a proliferating pipeline with 27 therapeutic candidates.

Get the detailed analysis @ https://www.pharmaproff.com/report/wnt-signaling-pathway-inhibitors

According to the research findings, majority of the drug candidates in the pipeline are being developed to be administered by the oral route. It has been observed that oral route of medications is convenient; available in delayed or rapid release formulation; provides improved patient’s compliance; and has less risk of systemic infections. Administration of Wnt Signaling Pathway Inhibitors through oral route has shown promising results in the clinical studies. Also, according to the analysis, maximum number of drugs in the pipeline are being developed as small molecules.

Positive Clinical Trial Results are Expected to Drive the Advancements in Wnt Signaling Pathway Inhibitors Pipeline

The companies developing Wnt Signaling Pathway inhibitors for the treatment of cancer and degenerative diseases, have shown positive clinical results in the various phases of drug development. For instance, in October 2018, Samumed LLC, announced the topline data from the phase IIb trial SM04690 in knee osteoarthritis, wherein the treatment with SM04690 showed improvement in function, pain, and global scores of patients.

Some of the key players involved in the development of Wnt signaling pathway inhibitors in the late and mid stage include Samumed LLC, Can-Fite BioPharma Ltd., Tactical Therapeutics Inc., Leap Therapeutics Inc., 2X Oncology Inc., Eisai Co. Ltd., and Novartis AG.

Myelodysplastic Syndromes (MDS) Epidemiology Insights

Myelodysplastic syndromes (MDS) can be described as a group of hematologic malignancies, that occurr due to abnormality in blood-forming cells in the bone marrow. It is a rare blood cancer and can be mild, moderate or severe, in terms of severity.

This syndrome can be classified into three main types: MDS with single lineage dysplasia wherein a single type of blood cell appears abnormal; multilineage dysplasia causing two or more cell types to appear abnormal; and MDS with excess blasts, wherein the patients have a shortage of either red blood cells, white blood cells or platelets. Some prominent risk factors that increase the risk of myelodysplastic syndromes are aging, exposure to industrial chemicals, chemo- or radiation therapy, and smoking.

MDS is an uncommon syndrome with an incidence of 4–5 patients per 100,000 populations. It increases with age and can reach up to 20–50 per 100,000 population, in patients aged over 60 years. According to a 2019 study, the annual incidence of pediatric MDS is approximately 1–4 cases/million, which accounts for less than 5% of childhood hematological malignancies.

Get the research study at: https://www.pharmaproff.com/request-sample/1162

Pipeline Analysis of Hormone Sensitive Breast Cancer Therapeutics

Breast cancer generally occurs when breast cells grow uncontrollably. Mostly, breast cancer development starts in the duct that carries milk to the nipples. Breast cancer generally occurs when breast cells grow uncontrollably. Mostly, breast cancer development starts in the duct that carries milk to the nipples.

Some breast cancer cells develop in milk producing glands. As per the National Institutes of Health (NIH), in the U.S., 14.6% of all new cancer cases diagnosed every year are of breast cancer. Also, as per the American Cancer Society (ACS), 1 in every 5 woman has cancer cell in their breast tumour with several growth promoting protein receptors on their surface. HER2 (human epidermal growth factor receptor 2) gene plays significant role in the development of breast cancer in most of the cases. Alpelisib is one of the key pipeline drug candidates for hormone sensitive breast cancer pipeline.

Get the Clinical Trials & Results of Hormone Sensitive Breast Cancer Therapeutics at: https://www.pharmaproff.com/request-sample/1114

Pfizer Inc., and Novartis AG are major players involved in the development of drugs for hormone sensitive breast cancer. Get the Clinical Trials & Results Report of Hormone Sensitive Breast Cancer Therapeutics at https://www.pharmaproff.com/request-sample/1114

Clinical Studies on Interleukin 8 Inhibitors Therapeutics

Interleukin 8 is a chemokine produced by various immune cells. They promote angiogenesis, proliferation and development of cancerous cells. The other diseases which are associated with interleukin 8 are depression, schizophrenia, bipolar disorder, migraine, Alzheimer’s disease, colitis, rheumatoid arthritis, multiple sclerosis, asthma, allergic rhinitis, psoriasis, eczema and others.

Interleukin 8 inhibitors therapies have shown improvements as anti-CXCL8 signalling inhibitors for the treatment of various diseases, including cancer and inflammatory diseases. Studies demonstrated that interleukin 8 can be indirectly targeted by mitogen activated protein kinase (MAPK) inhibitors, phosphatidylinositol-3-kinase (PI3K)/AKT inhibitors, and NF-κB inhibitors while direct targeting can be done by CXCL8 neutralizing antibodies, and other drug therapies such as Reparixin. Potent effects of interleukin 8 inhibitors therapeutics as chemo-modulators and anti-angiogenics are expected to treat various tumors

Bristol-Myers Squibb Company is in the process of developing HuMax-IL8 as a biologic which acts as an interleukin 8 inhibitor for the treatment of solid tumors. Dompé farmaceutici S.p.A. is another key player has interleukin 8 inhibitor pipeline therapeutics.

Download the Research Report about Interleukin 8 Inhibitors Therapeutics Pipeline Analysis at : https://www.pharmaproff.com/request-sample/1203

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Atypical Hemolytic Uremic Syndrome (aHUS) Therapeutics – Pipeline Analysis 2018

Atypical hemolytic uremic syndrome (aHUS), also known as non-diarrhea – associated hemolytic uremic syndrome, is a rare disease characterized by hemolytic anemia, thrombocytopenia, acute kidney failure and uremia.

The signs and symptoms of aHUS include formation of tiny blood clots in various small blood vessels of the body. These clots reduce or prevent proper blood flow to various organs of the body, especially the kidneys. aHUS is a complex disorder; and certain genetic, environmental and immunologic factors plays significant role in its development.

Download the Clinical Trials & Results of Atypical Hemolytic Uremic Syndrome (aHUS) Therapeutics at: https://www.pharmaproff.com/request-sample/1036

Company lile ChemoCentryx Inc. is in the process of developing avacopan, an orally-administered drug candidate, that inhibits the complement C5a receptor for the treatment of aHUS. Omeros Corporation, Greenovation Biotech GmbH, and Laboratoris Sanifit S.L. are some other companies developing therapeutic agents for aHUS.

Aurora Kinase Inhibitor Therapeutics Pipeline Analysis

Aurora kinase are proteins that function as mitotic regulators and are aberrantly expressed in cancerous cells. Aurora kinase inhibitors target these aberrantly expressed regulators, provides genetic stability and prevents tumorigenesis.

Several studies have demonstrated overexpression and amplification of aurora kinase in various haematological and solid cancers. Aurora kinase inhibitors when combined with other anti-cancer agents gives more positive results in variety of cancers. Better evaluation of aurora kinase inhibitors is required which raises the need of biomarkers, effective and novel therapeutic agents. Also, aurora kinase inhibitors selectivity targets cancer cells rather than healthy tissues, providing potential opportunities for more effective drug development with reduced adverse effects.

AstraZeneca PLC is in the process of developing AZD-2811 as a small molecule which acts as an aurora B inhibitor for the treatment of solid tumors. Some of the other companies having pipeline of aurora kinase inhibitors include AbbVie Inc., Merck & Co., Inc., and CASI Pharmaceuticals Inc.

For more information about Aurora Kinase Inhibitor Therapeutics Clinical Trials & Results Download the Research Report at: https://www.pharmaproff.com/request-sample/1174

Mitogen-Activated Protein Kinase (MAPK) Inhibitors Therapeutics Pipeline analysis

Mitogen-activated protein kinase (MAPK) are ubiquitous regulators of many cellular functions including cell proliferation, cellular growth, inflammatory responses to stress signals and cell differentiation. MAPK pathway, involves three main kinases, Raf, MEK and ERK, has emerged as a novel target for the development of new cancer therapies with reduced side-effects.

MAPK inhibitors are being developed as small molecules, for the treatment of various types of cancer. They have also showed additional benefits with high effectiveness at lower concentrations in comparison to the ATP-competitive inhibitors, for the cancer therapy.

Mereo BioPharma Group plc is in the process of developing Acumapimod as an oral p38 MAPK inhibitor for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). eFFECTOR Therapeutics Inc., Genentech Inc., and Kura Oncology Inc. are some other companies having pipeline of MAPK inhibitors.

For more info about Mitogen-Activated Protein Kinase (MAPK) Inhibitors Therapeutics Get the sample report at: https://www.pharmaproff.com/request-sample/1206

Sezary Syndrome Therapeutics Pipeline Analysis 2018

Sezary syndrome, a type of cutaneous T-cell lymphoma, affects Sézary cells present in the skin, lymph nodes and blood. It accounts approximately 3 to 5 percent of cases of cutaneous T-cell lymphoma.

Sézary syndrome is more prevalent in males compared to females. It is characterized by red, severely itchy rash that covers large areas of the body. The common symptoms of Sézary syndrome includes alopecia, lymphadenopathy, palmoplantar keratoderma, ectropion and abnormalities of the fingernails and toenails.

The standard treatments for Sézary syndrome are combination of phototherapy and chemotherapy, and medications including vorinostat and romidepsin. Takeda Pharmaceutical Company Limited is in the process of developing brentuximab vedotin for the treatment of Sézary syndrome.

For more information about Sezary Syndrome Therapeutics Pipeline Analysis request to get the sample report at: https://www.pharmaproff.com/request-sample/1118

Adrenocortical Carcinoma Therapeutics – Pipeline Analysis 2018

Adrenocortical carcinoma, also known as adrenal cortex carcinoma, is a rare form of cancer that occurs at the cortex layer of the adrenal gland. There are two adrenal glands present in the human body: one at the top of each kidney.

Each adrenal gland is comprised of two distinct structures: the outer part of the adrenal glands (adrenal cortex) and the inner region (adrenal medulla). Some of the genetic condition that can cause adrenocortical carcinoma are Li-Fraumeni syndrome, Carney complex, and Beckwith-Wiedemann syndrome.

Some of the most common symptoms of this medical condition includes abdominal pain, lump in the abdomen, and feeling of fullness. The disease can be diagnosed by imaging technique such as computed tomography (CT) scan, magnetic resonance imaging (MRI), biopsy, blood tests, and urine tests. Millendo Therapeutics Inc. is in the process of developing ATR-101 as an acetyl CoA C-acetyltransferase inhibitor for the treatment of adrenocortical carcinoma.

Merck & Co., Inc. is also in the process of developing pembrolizumab as a CD274 antigen inhibitor for the treatment of adrenocortical carcinoma. Some of the other companies and universities having the pipeline drug for adrenocortical carcinoma includes the Columbia University, Medunik Canada Inc., HRA Pharma, and others.

For more information about Adrenocortical Carcinoma Therapeutics pipeline analysis request to get a sample report at: https://www.pharmaproff.com/request-sample/1109

Clinical Trials & Results of MDM2 Protein Inhibitors Therapeutics

MDM2 protein are powerful oncogene which is overexpressed in various cancers, including breast cancer and sarcoma. There are many small molecule drug candidates that are being developed as MDM2 protein inhibitors as monotherapy or combination therapy for the treatment of various cancers. Combination therapies are more effective than monotherapy in certain cases. The therapeutic strategies aim at blocking MDM2 expression, blocking the physical interaction between MDM2 and p53, modulating the E3 ubiquitin ligase activity of MDM2 and targeting the MDM2-p53 (protein–protein) complex, for the treatment of various indications.

MDM2 protein therapies have shown positive clinical results for the treatment of various cancers. Also, researches have demonstrated that additional biomarkers are required to be identified to increase the chances of clinical success as mutations in p53 can lead to resistance to MDM2 inhibitors.

Daiichi Sankyo Company Limited is in the process of developing DS-3032 as a proto-oncogene protein C MDM2 inhibitor for the treatment of leukemia, and solid cancers. Some of the other companies having pipeline of MDM2 protein inhibitors include Aileron Therapeutics Inc., Amgen Inc., and F. Hoffmann-La Roche Ltd.

For more information about MDM2 Protein Inhibitors Therapeutics pipeline analysis get the sample report at: https://www.pharmaproff.com/request-sample/1205